一分钟看懂
这是一项关于前列腺癌的I 期 / II 期研究，登记的药物或干预包括Tulmimetostat；Darolutamide；Abiraterone；Prednisone/Prednisolone；Androgen Deprivation Therapy (ADT)，当前状态为招募中。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Tulmimetostat；Darolutamide；Abiraterone；Prednisone/Prednisolone；Androgen Deprivation Therapy (ADT) · I 期 / II 期
登记条件中文摘要
登记的基本范围为男性，年龄18 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Novartis Investigative Site · 广州
公开的入选条件
- * Adult men ≥ 18 years old with de novo or recurrent mHSPC (without neuroendocrine or small cell features). The tumor lesion(s) may be located in the bone, soft tissue/visceral region, or both.
- * Participants must have castrate levels of testosterone, i.e., ≤ 50 ng/dL (≤ 1.7 nM).
- * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
- * Adequate bone marrow and organ function
- * Prior ADT: Participants must have started ADT at least 1 month (at least 28 days) but no more than 12 months before study entry and be willing to continue ADT during treatment
- * Prior taxane use for mHSPC is permitted:
- Phase I and II: Participants may have received, but not progressed on, one prior taxane-based therapy.
- Phase II: Limited to 25% participants with prior taxane use.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07190300；登记信息更新于 2026-09-29。